Literature DB >> 11335065

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

P D Mehta1, T Pirttila, B A Patrick, M Barshatzky, S P Mehta.   

Abstract

We quantitated amyloid beta proteins 1-40 (Abeta40) and 1-42 (Abeta42), and alpha1- antichymotrypsin (ACT) in matched cerebrospinal fluid (CSF) and plasma of 50 patients with probable Alzheimer disease, and analyzed the relationships with age, sex, Mini-Mental State Examination (MMSE), and apolipoprotein E phenotype. There was no relation between CSF Abeta40 and Abeta42 levels with those of plasma. CSF and plasma Abeta40 and Abeta42 levels showed no association with age, sex, and MMSE score. There was a significant correlation between CSF ACT and plasma ACT levels. The data suggest that plasma ACT crosses the blood-brain barrier. However, a lack of correlation between CSF Abeta40 and Abeta42 levels with those of plasma suggests that Abeta in CSF and plasma originates from different sources.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11335065     DOI: 10.1016/s0304-3940(01)01754-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  65 in total

1.  Regenerable and simultaneous surface plasmon resonance detection of aβ(1-40) and aβ(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody.

Authors:  Ning Xia; Lin Liu; Michael G Harrington; Jianxiu Wang; Feimeng Zhou
Journal:  Anal Chem       Date:  2010-11-12       Impact factor: 6.986

2.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease.

Authors:  M Reale; M A Kamal; L Velluto; D Gambi; M Di Nicola; N H Greig
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes.

Authors:  Luanda Pym; Mark Kemp; Valérie Raymond-Delpech; Steven Buckingham; C A R Boyd; David Sattelle
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 4.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

Review 5.  Laboratory biomarkers in Alzheimer's disease.

Authors:  Joshua R Steinerman; Lawrence S Honig
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 6.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

7.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

8.  The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation.

Authors:  Sarah J Siegel; Jan Bieschke; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2007-02-13       Impact factor: 3.162

9.  Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity.

Authors:  Kenji Usui; John D Hulleman; Johan F Paulsson; Sarah J Siegel; Evan T Powers; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

Review 10.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.